{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:07:56Z","timestamp":1767982076757,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Substantial numbers of patients are now receiving either immunosuppressive therapies or chemotherapy. There are significant risks in such patients of developing opportunistic infections or re-activation of latent infections, with higher associated morbidity and mortality. The aim of this quality improvement project was to determine how effective 5 different specialties were in assessing and mitigating risks of developing opportunistic infections or re-activation of latent infections in patients undergoing immunosuppressive therapies.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a single centre audit where records of patients attending clinics providing immunosuppressive therapies were reviewed for the following: evidence of screening for blood-borne virus [BBV] infections, varicella and measles immunity, latent\/active TB or hypogammaglobulinaemia, and whether appropriate vaccines had been advised or various infection risks discussed. These assessments were audited against both national and international guidelines, or a cross-specialty consensus guideline where specific recommendations were lacking. Two sub-populations were also analysed separately: patients receiving more potent immunosuppression and black and minority ethnic [BME] patients,.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>For the 204 patients fulfilling the inclusion criteria, BBV, varicella\/measles and latent TB screening was inconsistent, as was advice for vaccinations, with few areas complying with specialty or consensus guidelines. Less than 10% of patients in one specialty were tested for HIV. In BME patients screening for HIV [60%], measles [0%] and varicella [40%] immunity and latent [30%] or active [20%] TB was low. Only 38% of patients receiving potent immunosuppression received <jats:italic>Pneumocystis<\/jats:italic> prophylaxis, with 3 of 4 specialties providing less than 15% of patients in this category with prophylaxis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Compliance with guidelines to mitigate risks of infection from immunosuppressive therapies was either inconsistent or poor for most specialties. New approaches to highlight such risks and assist appropriate pre-immunosuppression screening are needed.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05082-8","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T10:03:03Z","timestamp":1589968983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adherence to guidelines across different specialties to prevent infections in patients undergoing immunosuppressive therapies"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7955-9610","authenticated-orcid":false,"given":"David R.","family":"Chadwick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Sayeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Budd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaskiran","family":"Azad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Maddox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"5082_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/sj.bmt.1705964","volume":"41","author":"D Kumar","year":"2008","unstructured":"Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 2008;41:743\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"5082_CR2","doi-asserted-by":"publisher","unstructured":"Issacs, D. Infectious risks associated with biologics. In N Curtis et al. Hot topics in infection and immunity in children IX. Advances in experimental medicine and biology, 764, https:\/\/doi.org\/10.1007\/978-1-4726-9_12.","DOI":"10.1007\/978-1-4726-9_12"},{"issue":"8","key":"5082_CR3","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/ajg.2013.138","volume":"108","author":"AC Ford","year":"2013","unstructured":"Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108(8):1268\u201376. https:\/\/doi.org\/10.1038\/ajg.2013.138.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"5082_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/cid\/ciu185","volume":"58","author":"IS Kourbeti","year":"2014","unstructured":"Kourbeti IS, Ziakas PD, et al. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014;58(12):1649\u201357.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"5082_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.mcna.2016.01.008.17","volume":"100","author":"WG Greendyke","year":"2016","unstructured":"Greendyke WG, Pereira MR. Infectious complications and vaccinations in the post-transplant population. Med Clin North Am. 2016;100(3):587\u201398. https:\/\/doi.org\/10.1016\/j.mcna.2016.01.008.17.","journal-title":"Med Clin North Am"},{"issue":"2","key":"5082_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/ard.2008.089276","volume":"69","author":"JD Greenberg","year":"2010","unstructured":"Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69(2):380\u20136.","journal-title":"Ann Rheum Dis"},{"key":"5082_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3350\/cmh.2016.0024","volume":"22","author":"V Patullo","year":"2016","unstructured":"Patullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219\u201337.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"5082_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443\u201368.","journal-title":"J Crohns Colitis"},{"key":"5082_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607.","journal-title":"Gut"},{"key":"5082_CR10","volume-title":"Post-operative Care in the Kidney Transplant Recipient","author":"R Baker","year":"2017","unstructured":"Baker R, et al. Post-operative Care in the Kidney Transplant Recipient. 2017. https:\/\/bts.org.uk\/wp-content\/uploads\/2017\/06\/FINAL_PostOperative_Care_Guideline.pdf."},{"key":"5082_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.14136","volume":"174","author":"S Chaganti","year":"2016","unstructured":"Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174:43\u201356.","journal-title":"Br J Haematol"},{"key":"5082_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjd.14816","volume":"175","author":"RB Warren","year":"2016","unstructured":"Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016;175:23\u201344.","journal-title":"Br J Dermatol"},{"key":"5082_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.15665","volume":"177","author":"CH Smith","year":"2017","unstructured":"Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177:628\u2013136.","journal-title":"Br J Dermatol"},{"issue":"10","key":"5082_CR14","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2011.150193","volume":"70","author":"M W Heijstek","year":"2011","unstructured":"Heijstek MW, De Bruin LO, Bijl M, Borrow R, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.2011.150193.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"5082_CR15","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"Josef S Smolen","year":"2017","unstructured":"Josef S Smolen, Robert Landew\u00e9, Johannes Bijlsma, et al. 2016 Update of EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"5082_CR16","unstructured":"British Society of Rheumatology. Guidelines section. https:\/\/www.rheumatology.org.uk\/practice-quality\/guidelines. Accessed 16 May 2020."},{"key":"5082_CR17","unstructured":"Immunisation against infectious diseases. UK Government 2018. https:\/\/www.gov.uk\/government\/collections\/immunisation-against-infectious-disease-the-green-book."},{"key":"5082_CR18","unstructured":"UK National Institute for Health Care and Excellence. HIV testing: increasing uptake among people who may have undiagnosed HIV. 2016. https:\/\/www.nice.org.uk\/guidance\/ng60."},{"key":"5082_CR19","unstructured":"UK National Institute for Health Care and Excellence. Hepatitis B and C testing: people at risk of infection. 2013. https:\/\/www.nice.org.uk\/guidance\/ph43."},{"key":"5082_CR20","unstructured":"British HIV Association, British Association of Sexual Health and HIV, British Infection Society. UK National Guidelines for HIV Testing 2008. https:\/\/www.bhiva.org\/file\/RHNUJgIseDaML\/GlinesHIVTest08.pdf."},{"issue":"9","key":"5082_CR21","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"5082_CR22","first-page":"s203","volume":"50","author":"J Meiring","year":"2015","unstructured":"Meiring J, de Silva TI, Snowden JA. A study of adherence to a vaccination schedule following adult allogeneic haematopoietic stem cell transplants in UK transplant centre. Bone Marrow Transplant. 2015;50(Suppl 1):s203\u20134 [abtract P171].","journal-title":"Bone Marrow Transplant"},{"key":"5082_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/bmt.2016.362","volume":"52","author":"PDE Miller","year":"2017","unstructured":"Miller PDE, da Silber I, Skinner R, et al. Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes. Bone Marrow Transplant. 2017;52:775\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5082_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1432-2277.2005.00218.x","volume":"19","author":"FM Marty","year":"2006","unstructured":"Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int. 2006;19(1):2\u201311.","journal-title":"Transpl Int"},{"issue":"Suppl 4","key":"5082_CR25","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1111\/j.1600-6143.2009.02888.x","volume":"9","author":"SA Fischer","year":"2009","unstructured":"Fischer SA, Avery RK. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009;9(Suppl 4):S7\u201318.","journal-title":"Am J Transplant"},{"key":"5082_CR26","unstructured":"Working party of the British Transplant Society. British Guidelines for Hepatitis B & Solid Organ Transplantation. 2018. https:\/\/bts.org.uk\/wp-content\/uploads\/2018\/03\/BTS_HepB_Guidelines_FINAL_09.03.18.pdf."},{"key":"5082_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/cid\/civ287","volume":"61","author":"C Cordonnier","year":"2015","unstructured":"Cordonnier C, Ljungman P, Juergens C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >\/= 2 years: an open-label study. Clin Infect Dis. 2015;61:313\u201323.","journal-title":"Clin Infect Dis"},{"key":"5082_CR28","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44\u2013100.","journal-title":"Clin Infect Dis"},{"key":"5082_CR29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/bmjqs-2015-003957","volume":"24","author":"R Clay-Williams","year":"2015","unstructured":"Clay-Williams R, Colligan L. Back to basics: checklists in aviation and healthcare. BMJ Qual Safety. 2015;24:428\u201331.","journal-title":"BMJ Qual Safety"},{"key":"5082_CR30","doi-asserted-by":"publisher","unstructured":"Li RC, Wang JK, Sharp C, et al. When order sets do not align with clinician workflow: assessing practice patterns in the electronic health record. BMJ Qual Saf Published Online First: 04 June 2019. https:\/\/doi.org\/10.1136\/bmjqs-2018-008968.","DOI":"10.1136\/bmjqs-2018-008968"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05082-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T07:12:42Z","timestamp":1621494762000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05082-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5082"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05082-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This project received approval from the South Tees Hospitals NHS Foundation Trust Audit Department and no research ethics approval was required. No consent from patients was required. Data was anonymised prior to use and analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No authors have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}